Università Vita-salute San Raffaele

This study is for people with advanced non-small cell lung cancer (NSCLC) who have a specific biomarker that puts them at high risk for a dangerous side effect called hyperprogression, where immunotherapy can cause tumors to grow much faster. Researchers want to see if starting t…